Novel neural pathways targeted by GLP-1R agonists and bariatric surgery

Area of Science:

• Neuroscience
• Endocrinology
• Bariatric Medicine

Background:

• Glucagon-like peptide 1 receptor (GLP-1R) agonists like semaglutide offer new obesity treatments.
• Bariatric surgery is a proven, long-term solution for severe obesity.
• Both interventions suppress appetite by acting on the brain, though mechanisms are not fully understood.

Purpose of the Study:

• To review recent preclinical studies on the neural control of food intake and body weight.
• To explore the roles of endogenous GLP-1, GLP-1R agonists, and bariatric surgery in weight regulation.
• To elucidate the commonalities and differences in how these interventions target the brain.

Main Methods:

• Review of contemporary neuroscientific techniques and preclinical studies.
• Tracing neural pathways from the periphery (vagal, intestinofugal, spinal nerves) to the brainstem, hypothalamus, and non-canonical feeding centers (zona incerta, lateral septum).

Main Results:

• GLP-1R agonists and bariatric surgery converge on neural pathways controlling food intake and body weight.
• Evidence suggests these interventions modulate appetite signaling from the gut to the brain.
• Specific brain regions, including the hypothalamus and zona incerta, are implicated in their effects.

Conclusions:

• Identifying shared and distinct neural targets of GLP-1R agonists and bariatric surgery can bridge pharmacological and surgical approaches.
• Understanding these neural mechanisms may inform combined treatment strategies for enhanced weight loss.
• This review provides a neural basis for optimizing obesity interventions.